As a follow-up to last week’s rant, when I was in Israel we met with a company that produces healthcare IT solutions with the goal of making it easier for doctors and hospitals to transfer patient information quickly and accurately. A venture capital partner whose company provided much of the funding for the startup also attended the meeting and answered questions. One of my colleagues asked her the following: “since this company is making a product that can potentially save lives, would you accept a lower rate of return on your investment than you would otherwise?” Her answer was a terse, “No.” She went on to explain that the large technology companies that owned much of the equity in her company, the venture capital firm, would not allow such a thing because of their need to return market-competitive profits to their shareholders.